Germany
· Delayed Price · Currency is EUR Sino Biopharmaceutical Statistics
Total Valuation
FRA:SMZ1 has a market cap or net worth of EUR 8.02 billion. The enterprise value is 8.74 billion.
| Market Cap | 8.02B |
| Enterprise Value | 8.74B |
Important Dates
The next estimated earnings date is Friday, May 16, 2025.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.26% |
| Shares Change (QoQ) | -1.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.85B |
Valuation Ratios
The trailing PE ratio is 17.31.
| PE Ratio | 17.31 |
| Forward PE | n/a |
| PS Ratio | 2.10 |
| PB Ratio | 1.42 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 18.88 |
| EV / Sales | 2.51 |
| EV / EBITDA | 12.09 |
| EV / EBIT | 14.34 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.26 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | n/a |
| Interest Coverage | 17.51 |
Financial Efficiency
Return on equity (ROE) is 11.82% and return on invested capital (ROIC) is 6.25%.
| Return on Equity (ROE) | 11.82% |
| Return on Assets (ROA) | 5.01% |
| Return on Invested Capital (ROIC) | 6.25% |
| Return on Capital Employed (ROCE) | 11.27% |
| Revenue Per Employee | 156,688 |
| Profits Per Employee | 18,997 |
| Employee Count | 24,379 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +41.49% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 58.14 |
| Average Volume (20 Days) | 25,072 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:SMZ1 had revenue of EUR 3.82 billion and earned 463.14 million in profits. Earnings per share was 0.03.
| Revenue | 3.82B |
| Gross Profit | 3.11B |
| Operating Income | 684.00M |
| Pretax Income | 698.37M |
| Net Income | 463.14M |
| EBITDA | 808.37M |
| EBIT | 684.00M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 1.93 billion in cash and 1.29 billion in debt, giving a net cash position of 636.97 million.
| Cash & Cash Equivalents | 1.93B |
| Total Debt | 1.29B |
| Net Cash | 636.97M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.66B |
| Book Value Per Share | 0.24 |
| Working Capital | 678.71M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 81.51%, with operating and profit margins of 17.91% and 12.12%.
| Gross Margin | 81.51% |
| Operating Margin | 17.91% |
| Pretax Margin | 18.28% |
| Profit Margin | 12.12% |
| EBITDA Margin | 21.16% |
| EBIT Margin | 17.91% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 1.60%.
| Dividend Per Share | 0.01 |
| Dividend Yield | 1.60% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.26% |
| Shareholder Yield | 2.86% |
| Earnings Yield | 5.78% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.
| Last Split Date | Jul 20, 2020 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |